A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

References

• Moik F, Colling M, Mahé I, et al. Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost. 2022;20(3):619–634.
   PubMed Web of Science ®Google Scholar
• Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490–493.
   PubMed Web of Science ®Google Scholar
• All-Party Parliamentary Thrombosis Group. Venous thromboembolism (VTE) in cancer patients: cancer, chemotherapy and clots; 2015. Available from: http://apptg.org.uk/wp-content/uploads/2016/12/VTE-in-Cancer-Patients-2015.pdf#:∼:text=Of%20the%20patients%20who%20died%20of%20cancer%20in,underestimate%20of%20the%20true%20scale.%20High%20Risk%20Cancers.
   Google Scholar
• Fuentes HE, Tafur AJ, Caprini JA. Cancer-associated thrombosis. Dis Mon. 2016;62(5):121–158.
   PubMed Web of Science ®Google Scholar
• Nicholson M, Chan N, Bhagirath V, et al. Prevention of venous thromboembolism in 2020 and beyond. J Clin Med. 2020;9(8):2467.
   PubMed Web of Science ®Google Scholar
• Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10(10):380.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Katholing A, Rietbrock S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117(1):57–65.
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Baker WL, Smith E, et al. Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost. 2018;24(9_suppl):182s–187s.
   PubMedGoogle Scholar
• van der Wall SJ, Klok FA, den Exter PL, et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost. 2017;15(1):74–79.
   PubMed Web of Science ®Google Scholar
• McBane IR, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421.
   PubMed Web of Science ®Google Scholar
• Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol. 2014;8:CMO.S18991.
   Google Scholar
• Agnelli G, Becattini C, Meyer G, Caravaggio Investigators, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, Hokusai VTE Cancer Investigators, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Mulder FI, van Es N, Kraaijpoel N, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE cancer study. Thromb Res. 2020;185:13–19.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Marshall A, Levine M, Hill C, et al. Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D trial (SELECT‐D: 12m). J Thromb Haemost. 2020;18(4):905–915.
   PubMed Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, CASTA DIVA Trial Investigators, et al. Rivaroxaban vs. dalteparin in cancer-associated thromboembolism: a randomized trial. CHEST. 2022;161(3):781–790.
   PubMed Web of Science ®Google Scholar
• Musgrave KM, Power K, Laffan M, et al. Practical treatment guidance for cancer-associated thrombosis – managing the challenging patient: a consensus statement. Crit Rev Oncol Hematol. 2022;171:103599.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974.
   PubMed Web of Science ®Google Scholar
• Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608.
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–1303.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing [NG158]; 2020. Available from: https://www.nice.org.uk/guidance/ng158.
   Google Scholar
• Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158–163.
   PubMed Web of Science ®Google Scholar
• European Society of Cardiology. ESC guidelines on cardio-oncology; 2022. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Cardio-oncology-guidelines.
   Google Scholar
• Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120(7):1128–1136.
   PubMed Web of Science ®Google Scholar
• Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136(12):1433–1441.
   PubMed Web of Science ®Google Scholar
• Riaz IB, Fuentes HE, Naqvi SAA, et al. Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis. Mayo Clin Proc. 2022;97(2):308–324.
   PubMed Web of Science ®Google Scholar
• Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136(3):582–589.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE cancer study. J Thromb Haemost. 2019;17(11):1866–1874.
   PubMed Web of Science ®Google Scholar
• Mahé I, Agnelli G, Ay C, et al. Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT study. Thromb Haemost. 2022;122(4):646–656.
   PubMedGoogle Scholar
• McBane RD, 2nd, Loprinzi CL, Ashrani A, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: the EVE trial. Eur J Haematol. 2020;104(2):88–96.
   PubMed Web of Science ®Google Scholar
• Schaefer JK, Li M, Wu Z, et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost. 2021;19(1):212–220.
   PubMed Web of Science ®Google Scholar
• Li A, Manohar PM, Garcia DA, et al. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019;180:37–42.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
   Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e581.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891–1894.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Lixiana 60mg film-coated tablets – summary of product characteristics (SmPC); 2022. Availbale from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf.
   Google Scholar
• Kim JH, Yoo C, Seo S, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers. 2022;14(3):559.
   PubMed Web of Science ®Google Scholar
• Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(8):1439–1449.
   PubMed Web of Science ®Google Scholar
• Ingason AB, Hreinsson JP, Ágústsson AS, et al. Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study. Ann Intern Med. 2021;174(11):1493–1502.
   PubMed Web of Science ®Google Scholar
• Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616–624.
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Skalij P, Tokajuk P, et al. Direct oral anticoagulants in cancer patients. Time for a change in paradigm. Cancers. 2020;12(5):1144.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Muñoz A, Franco L, et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796–807.
   PubMedGoogle Scholar
• Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv. 2020;4(24):6291–6297.
   PubMed Web of Science ®Google Scholar
• Picker N, Lee AY, Cohen AT, et al. Anticoagulation treatment in cancer-associated venous thromboembolism: assessment of patient preferences using a discrete choice experiment (COSIMO study). Thromb Haemost. 2021;121(2):206–215.
   PubMedGoogle Scholar
• Verso M, Agnelli G, Munoz A, et al. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer. 2022;165:136–145.
   PubMed Web of Science ®Google Scholar
• Marin A, Bull L, Kinzie M, et al. Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Support Palliat Care. 2021;11(4):371–380.
   PubMed Web of Science ®Google Scholar
• Sousa B, Furlanetto J, Hutka M, et al. Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol. 2015;26:v152–v168.
   PubMedGoogle Scholar
• Zwicker JI, Connolly G, Carrier M, et al. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(5):796–800.
   PubMed Web of Science ®Google Scholar
• Davies GA, Lazo-Langner A, Gandara E, et al. A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res. 2018;162:88–92.
   PubMed Web of Science ®Google Scholar
• Ross JA, Miller MM, Rojas Hernandez CM. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86–89.
   PubMed Web of Science ®Google Scholar
• Peixoto de Miranda ÉJF, Takahashi T, Iwamoto F, et al. Drug–drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms. Clin Appl Thromb Hemost. 2020;26:1076029620936325.
   Web of Science ®Google Scholar
• Verso M, Munoz A, Bauersachs R, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371–381.
   PubMed Web of Science ®Google Scholar
• Beavers CJ, Rodgers JE, Bagnola AJ, American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease, et al. Cardio-Oncology drug interactions: a scientific statement from the American heart association. Circulation. 2022;145(15):e811–e838.
   PubMed Web of Science ®Google Scholar
• Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: systematic review and meta-analysis. J Thromb Haemost. 2020;18(7):1661–1671.
   PubMed Web of Science ®Google Scholar
• Hutchinson A, Rees S, Young A, et al. Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliat Med. 2019;33(5):510–517.
   PubMed Web of Science ®Google Scholar
• Toorop MMA, van Rein N, Nierman MC, et al. Switching from vitamin K antagonists to direct oral anticoagulants: treatment satisfaction and patient concerns. J Thromb Haemost. 2020;18(6):1390–1397.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Maraveyas A, Beyer-Westendorf J, COSIMO Investigators, et al. Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – the COSIMO study. Thromb Res. 2021;206:1–4.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Curr Med Res Opin. 2021;:1–16. DOI:10.1080/03007995.2021.1932448
   PubMed Web of Science ®Google Scholar
• Desai R, Koipallil GK, Thomas N, et al. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep. 2020;10(1):18945.
   PubMed Web of Science ®Google Scholar
• Barbosa CD, Balp MM, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48.
   PubMed Web of Science ®Google Scholar
• Noble S. Venous thromboembolism and palliative care. Clin Med. 2019;19(4):315–318.
   PubMed Web of Science ®Google Scholar
• Becattini C, Bauersachs R, Maraziti G, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. haematol. 2021;107(7):1567–1576.
   Web of Science ®Google Scholar
• Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. Eur J Haematol. 2019;102(4):312–318.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Eliquis 2.5mg film-coated tablets - summary of product characteristics (SmPC); 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.
   Google Scholar
• Sun L, Yin H, Liu M, et al. Impaired albumin function: a novel potential indicator for liver function damage? Ann Med. 2019;51(7–8):333–344.
   PubMed Web of Science ®Google Scholar
• Riess H, Ay C, Bauersachs R, et al. Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting. Oncologist. 2018;23(7):822–839.
   PubMed Web of Science ®Google Scholar
• Puhr HC, Ilhan-Mutlu A, Preusser M, et al. Absorption of direct oral anticoagulants in cancer patients after gastrectomy. Pharmaceutics. 2022;14(3):662.
   PubMed Web of Science ®Google Scholar
• Dunois C. Laboratory monitoring of direct oral anticoagulants (DOACs). Biomedicines. 2021;9(5):445.
   PubMed Web of Science ®Google Scholar
• Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation. J Thromb Haemost. 2021;19(8):1874–1882.
   PubMed Web of Science ®Google Scholar
• Martin AC, Thomas W, Mahir Z, et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost. 2021;121(2):224–233.
   PubMed Web of Science ®Google Scholar
• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Eng J Med. 2013;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Bravo Villa V, Romero J, Rojas-Zaldivar E, et al. Apixaban in low-weight patients with cancer-associated thrombosis: a cross sectional study of drug levels. Res Pract Thromb Haemost. 2021;5(3):421–425.
   PubMed Web of Science ®Google Scholar
• Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med. 2018;18(4):314–319.
   PubMed Web of Science ®Google Scholar
• Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246–1249.
   PubMed Web of Science ®Google Scholar
• Makris M, Van Veen JJ, Tait CR, British Committee for Standards in Haematology, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160(1):35–46.
   PubMed Web of Science ®Google Scholar
• Moik F, Posch F, Zielinski C, et al. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4(4):550–561.
   PubMed Web of Science ®Google Scholar
• Alpert N, Rapp JL, Marcellino B, et al. Clinical course of cancer patients with COVID-19: a retrospective cohort study. JNCI Cancer Spectr. 2021;5(1):Pkaa085.
   PubMed Web of Science ®Google Scholar
• Brenner B, Ay C, Gal GL, et al. Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: an unmet medical need. Thrombosis Update. 2022;6:100098.
   Google Scholar
• National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19 [NG191]; 2022. Available from: https://www.nice.org.uk/guidance/ng191.
   Google Scholar
• Schulman S, Sholzberg M, Spyropoulos AC, International Society on Thrombosis and Haemostasis, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022;20(10):2214–2225.
   PubMed Web of Science ®Google Scholar
• Radboud UMC and University of Liverpool. Liverpool COVID-19 drug interactions; 2022. Available from: https://covid19-druginteractions.org/about.
   Google Scholar